Home Cardiome Pharma Corp (CRME) Receives "Buy" Rating from Canaccord Genuity
 

Keywords :   


Cardiome Pharma Corp (CRME) Receives "Buy" Rating from Canaccord Genuity

2016-03-13 15:32:23| Biotech - Topix.net

's stock had its "buy" rating reaffirmed by investment analysts at Canaccord Genuity in a research report issued on Sunday, AnalystRatings.NET reports. They presently have a $10.00 target price on the biopharmaceutical company's stock.

Tags: buy rating corp receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
03.06Sony Pictures Networks extends distribution deal with Intelsat
03.06India's SVOD market to generate $2.1 billion in 2028
03.06MEASAT supports SPOTV Asia Pacific playout operations
03.06Eastern North Pacific Tropical Weather Outlook
03.06Atlantic Tropical Weather Outlook
03.06Could a housing revolution transform Canadian cities?
02.06Eastern North Pacific Tropical Weather Outlook
02.06Atlantic Tropical Weather Outlook
More »